A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.
McCormack S, Tilzey A, Carmichael A, Gotch F, Kepple J, Newberry A, Jones G, Lister S, Beddows S, Cheingsong R, Rees A, Babiker A, Banatvala J, Bruck C, Darbyshire J, Tyrrell D, Van Hoecke C, Weber J.
McCormack S, et al. Among authors: van hoecke c.
Vaccine. 2000 Jan 18;18(13):1166-77. doi: 10.1016/s0264-410x(99)00388-6.
Vaccine. 2000.
PMID: 10649617
Clinical Trial.